InvestorBrandNetwork (IBN) logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

InvestorNewsBreaks – Roth Canada Launches Institutional Trading Platform, Appoints Chris Bond Head of Trading

November 16, 2026 — Roth Canada, the Canadian affiliate of ROTH Capital Partners, announced the launch of its Canadian institutional trading platform, expanding its domestic sales and trading capabilities and cross-border services for Canadian-listed companies and institutional investors. The firm has been accepted as a trading member of the Toronto Stock Exchange (“TSX”) and TSX Venture Exchange (“TSXV”) and as a member of Alpha Exchange.


NetworkNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTFD) Featured in AINewsWire Editorial Highlighting $9 Million Semiconductor Equipment Revenue Opportunity

November 16, 2026 — Nightfood Holdings (OTCQB: NGTFD), doing business as TechForce Robotics, was featured in an AINewsWire editorial examining growing demand for semiconductor manufacturing equipment driven by artificial intelligence (“AI”) infrastructure expansion. The editorial highlighted the company’s efforts to commercialize automated optical inspection (“AOI”) technology through its subsidiary, TechForce Advanced Manufacturing Inc.


RockBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Intersects 2.52 g/t Gold Over 14.35 Meters, Extends Swanson Deposit 90 Meters West

November 16, 2026 — This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising. LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) reported assay results from its fall 2026 drilling program at the Swanson Gold Deposit, highlighting near-surface gold mineralization that extends the deposit approximately 90 meters west along strike from the planned starter pit.


Personalized Vaccines are Giving More Patients Hope After Brain Cancer Diagnosis

November 16, 2026 — Personalized vaccines are giving more brain cancer patients reason to hope, and at UCLA, one tested in clinical trials has helped about two dozen people with glioblastoma live far longer than expected. Doctors are now working to extend that benefit to the thousands of brain tumor patients who need it.


3 Factors Gold Investors Need to Watch Beyond Monthly Inflation Reports

November 16, 2026 — October’s inflation data came in hotter than had been forecast, and gold prices dropped on that news. The decline was because sticky inflation increases the odds of a Fed rate hike, and higher interest rates lure investors from non-yielding assets to assets like bonds that offer a real yield.


Quantum Computing Could Transform Drug Discovery, But Caveats Remain

November 16, 2026 — Finding new medicines is a long and expensive process, mostly because scientists must understand how thousands of chemical compounds behave and interact with the human body. Traditional computers have helped researchers handle these tasks, but some molecular problems remain difficult to solve.


MissionIRNewsBreaks – Wrap Technologies, Inc. (NASDAQ: WRAP) Announces Military-Standard Certification of Frenel Imaging Detection System for WrapShield(TM) Platform

November 16, 2026 — Wrap Technologies (NASDAQ: WRAP) announced that its WrapShield(TM) detection partner, Frenel Imaging Ltd. , has completed integration of its TPiCore(R) polarimetric thermal sensing technology and edge processing capabilities into an operational dual-channel electro-optical gimbal manufactured by a leading defense contractor.


NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 3 Results for HLP003 in Major Depressive Disorder, Meeting Primary and Key Secondary Endpoints

November 16, 2026 — This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced positive topline results from APPROACH, its pivotal Phase 3 trial evaluating HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (“MDD”).